Johnson & Johnson (JNJ) Presents at UBS MedTech, Tools and Genomics Summit Conference (Transcript)


Johnson & Johnson (NYSE:JNJ) UBS MedTech, Tools and Genomics Summit Conference Call August 15, 2023 2:00 PM ET

Company Participants

Celine Martin – Group Chairman

Jasmina Brooks – President, Biosense Webster

Anthony Hong – Vice President, Preclinical and Clinical Research and Medical Affairs

Conference Call Participants

Danielle Antalffy – UBS

Danielle Antalffy

Alright. Good morning, everyone. My name is Danielle Antalffy, the med-tech analyst here at UBS. And we are very lucky to have with us on this very exciting fireside chat the Johnson & Johnson Biosense Webster team. We are represented in full force here. Celine Martin, the company Group Chairman of CSS, sorry, I guess, more than just Biosense Webster; we have Jasmina Brooks, the President of Biosense Webster; and Anthony Hong, VP Preclinical and Clinical Research and Medical Affairs. I know it’s probably up there. But anyway, thank you, guys, for joining. It’s a very exciting time in electrophysiology. And a lot is happening and a lot is going to happen over the next few months.

So maybe let’s get a start level setting. Biosense Webster is the very clear market leader today in electrophysiology. Can you talk, Celine, about how the EP market has evolved over the last decade? And how do you see it evolving over the next few years with post-field ablation new technology coming online?

Celine Martin

Sure. Happy to. First, thank you for having us. It’s a pleasure to be here. And I will say that having been in the space for 20 years, it’s very rewarding to be talking today about how much we’ve come. We’ve come a long way in terms of the AF ablation established as a standard of care.

So maybe as a starting point, let me spend some time talking about AFib as a disease state, number one. So AFib



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *